Kitai Takeshi, Kim Yong-Hyun, Kiefer Kathryn, Morales Rommel, Borowski Allen G, Grodin Justin L, Tang W H Wilson
Kaufman Center for Heart Failure, Department of Cardiovascular Medicine, Heart and Vascular Institute, Cleveland Clinic, Cleveland, OH, United States.
Department of Cellular and Molecular Medicine, Lerner Research Institute, Cleveland, OH, United States.
Clin Biochem. 2017 Jun;50(9):491-495. doi: 10.1016/j.clinbiochem.2017.02.014. Epub 2017 Feb 20.
Venous congestion has become increasingly recognized as a potential contributor to end-organ dysfunction in heart failure. Elevated I-FABP, which is excreted specifically from damaged intestinal epithelial cells, has been found in patients with abdominal hypertension and intestinal ischemia. We hypothesize that elevated intestinal fatty acid-binding protein (I-FABP) levels would identify patients with more advanced heart failure who have venous and intestinal congestion.
Baseline serum I-FABP levels were measured in 69 acute decompensated heart failure (ADHF) patients admitted to the intensive care unit for invasive hemodynamic monitoring and tailored medical therapy. Comprehensive echocardiography examinations were performed in all study patients, and clinical outcomes (death, cardiac transplant or left ventricular assist device placement) were assessed.
The median circulating I-FABP level was 853pg/ml (interquartile range: 533 to 1448pg/ml). Age, gender, race, and baseline comorbidities were comparable between patients with low and high I-FABP levels. Although there were no significant correlations between I-FABP levels and invasively-measured hemodynamic parameters nor echocardiographic parameters, patients with higher I-FABP levels (≥853g/ml) had significantly worse clinical outcomes compared to those with lower I-FABP levels (<853pg/ml, P=0.025).
Circulating I-FABP levels had no association with invasively-measured hemodynamic parameters, but were associated with adverse clinical outcomes in patients with ADHF with systolic dysfunction.
静脉淤血日益被认为是导致心力衰竭终末器官功能障碍的一个潜在因素。在腹内高压和肠道缺血患者中发现,从受损肠上皮细胞特异性分泌的肠脂肪酸结合蛋白(I-FABP)水平升高。我们假设,升高的肠脂肪酸结合蛋白(I-FABP)水平可识别出存在静脉和肠道淤血的更晚期心力衰竭患者。
对69例因有创血流动力学监测和个体化药物治疗而入住重症监护病房的急性失代偿性心力衰竭(ADHF)患者,测定其基线血清I-FABP水平。对所有研究患者进行全面超声心动图检查,并评估临床结局(死亡、心脏移植或植入左心室辅助装置)。
循环I-FABP水平的中位数为853pg/ml(四分位间距:533至1448pg/ml)。I-FABP水平低和高的患者在年龄、性别、种族和基线合并症方面具有可比性。尽管I-FABP水平与有创测量的血流动力学参数及超声心动图参数之间无显著相关性,但与I-FABP水平较低者(<853pg/ml)相比,I-FABP水平较高者(≥853pg/ml)的临床结局明显更差(P=0.025)。
循环I-FABP水平与有创测量的血流动力学参数无关,但与收缩功能障碍的ADHF患者的不良临床结局相关。